Lv2
116 积分 2021-10-27 加入
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
16天前
已完结
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
16天前
已完结
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
16天前
已完结
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
16天前
已完结
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
16天前
已完结
Endometrial Cancer
18天前
已完结
Cancer burden and control in China: landscape, trends and challenges
18天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
1个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1个月前
已完结
皖公网安备34019202002308
